CA2957046C — Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
Assigned to Nuevolution AS · Expires 2022-11-15 · 4y expired
What this patent protects
Disclosed are compounds of Formula (I): (see formula (I) active towards nuclear receptors. Also disclosed are pharmaceutical compositions containing the compounds and use of the compound in therapy, for example, for inflammatory, metabolic, oncologic and autoimmune diseases.
USPTO Abstract
Disclosed are compounds of Formula (I): (see formula (I) active towards nuclear receptors. Also disclosed are pharmaceutical compositions containing the compounds and use of the compound in therapy, for example, for inflammatory, metabolic, oncologic and autoimmune diseases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.